TOKYO--(BUSINESS WIRE)--RevolKa Ltd. (RevolKa), a venture-backed biotech company providing a cutting-edge AI-driven protein engineering technology platform, called aiProtein® announced the closing of a 100 million JPY (US$0.7M) financing, and has completed a total of 250 million JPY (US$1.7M) in the Series A extension funding.

东京--（商业新闻短讯）--RevolKa Ltd.（RevolKa），一家由风险投资支持的生物技术公司，提供尖端的人工智能驱动的蛋白质工程技术平台，名为aiProtein®，宣布关闭1亿日元（70万美元）的融资，并已完成a系列延期资金总计2.5亿日元（170万美元）。

We also announced the launch of a drug discovery program for rare diseases on July 30th, 2024. (https://www.revolka.com/news/english/collab-en/a65) Some of our drug candidates in this program have achieved positive in vitro proof-of-concept. D3 LLC (Tomoya Nagata, Managing Partner, CEO) co-led the Series A extension round along with DEEPCORE Inc.

我们还宣布于2024年7月30日启动罕见疾病药物发现计划。（笑声）(https://www.revolka.com/news/english/collab-en/a65)我们在这个项目中的一些候选药物已经取得了积极的体外概念验证。D3 LLC（Tomoya Nagata，管理合伙人，首席执行官）与DEEPCORE Inc.共同领导了A轮延期。

(Katsumasa Niki, President & CEO). The funds will accelerate RevolKa’s drug discovery and development activities..

（总裁兼首席执行官Katsumasa Niki）。这些资金将加速RevolKa的药物发现和开发活动。。

Our core technology, aiProtein®: a robust directed protein evolution technology integrated with AI (artificial intelligence) creates incredibly high performance proteins, going beyond natural evolution. This technology generated many successful stories in collaboration with partner companies.

我们的核心技术aiProtein®：一种强大的定向蛋白质进化技术，与人工智能（AI）相结合，创造出令人难以置信的高性能蛋白质，超越了自然进化。这项技术与合作伙伴公司合作产生了许多成功的故事。

About D3 LLC

关于D3 LLC

D3.LLC, founded in 2017, is a healthcare-focused investment, business, and consulting company. Our mission is to contribute to global healthcare. We go beyond funding promising scientific and technological seeds and business ideas (Discovery), working alongside entrepreneurs to create meaningful products and services and build business models to deliver them to market (Development).

D3.LLC成立于2017年，是一家专注于医疗保健的投资、商业和咨询公司。我们的使命是为全球医疗保健做出贡献。我们不仅资助有前途的科技种子和商业想法（发现），还与企业家合作，创造有意义的产品和服务，建立商业模式，将其推向市场（开发）。

We aim for the social implementation of science, technology, and ideas (Deployment). In venture-capital activities, we value investing in a selected company and providing hands-on support to them in accordance with global standards in the biotech and healthcare VC..

我们的目标是科学、技术和思想的社会实施（部署）。。。

About DEEPCORE Inc.

关于DEEPCORE Inc。

DEEPCORE Inc. is a venture capital focused on companies in the fields of AI and advanced technologies, supporting entrepreneurs who have the vision to change the world through technology. We invest in pre-seed to early-stage startups in a wide range of industries and sectors, including healthcare, manufacturing, and logistics.

DEEPCORE Inc.是一家风险投资公司，专注于人工智能和先进技术领域的公司，支持有远见通过技术改变世界的企业家。我们投资于包括医疗保健、制造业和物流业在内的广泛行业和部门的种子前期到早期创业公司。

In addition to investment activities, we also focus on supporting entrepreneurs. For instance, we are operating 'KERNEL', a community of AI engineers, researchers, and entrepreneurs, and 'KERNEL Global Startup Camp', an accelerator program focused on early-stage startups looking to expand their business overseas..

除了投资活动外，我们还专注于支持企业家。例如，我们正在运营“内核”（一个由人工智能工程师、研究人员和企业家组成的社区）和“内核全球创业营”（一个专注于希望在海外拓展业务的早期初创公司的加速器计划）。。

About aiProtein® Technology

关于aiProtein®技术

RevolKa’s proprietary technology, aiProtein® is an AI-assisted directed evolution of proteins. Naturally occurring protein is a linear polymer of amino acids and their derivatives, which folds into a tertial structure through internal complex atomic interactions to show biological function. Proteins have evolved into biologically functional molecules over hundreds of millions of years.

RevolKa的专有技术aiProtein®是人工智能辅助的蛋白质定向进化。天然存在的蛋白质是氨基酸及其衍生物的线性聚合物，通过内部复杂的原子相互作用折叠成三级结构以显示生物学功能。几亿年来，蛋白质已经进化成具有生物功能的分子。

The relationship between protein sequence, structure, and function in those highly complex molecules remains poorly understood to rationally design a protein sequence for a particular function. Our AI engine is trained with sequence-function relationship data to statistically predict sequences for an evolved protein function.

这些高度复杂的分子中蛋白质序列，结构和功能之间的关系仍然知之甚少，无法合理设计特定功能的蛋白质序列。我们的AI引擎使用序列-功能关系数据进行训练，以统计预测进化蛋白质功能的序列。

Furthermore, aiProtein® can evolve more than two functions simultaneously. This technology is a powerful and cost-effective tool for the creation of novel and highly functional proteins for pharmaceutical and industrial uses..

此外，aiProtein®可以同时进化两种以上的功能。这项技术是一种强大且具有成本效益的工具，可用于制药和工业用途的新型高功能蛋白质的产生。。

About RevolKa Ltd.

关于RevolKa Ltd。

RevolKa is a venture-backed biotechnology company founded in April 2021 by academic and industry experts in biotechnology and artificial intelligence. Our mission is to create novel proteins useful for therapeutics and industries by using our own proprietary technology, aiProtein® to contribute to human well-being.

RevolKa是一家由风险投资支持的生物技术公司，由生物技术和人工智能领域的学术和行业专家于2021年4月成立。我们的使命是通过使用我们自己的专有技术aiProtein®来创造对治疗和工业有用的新型蛋白质，为人类福祉做出贡献。

The name 'RevolKa' is derived from the Latin word for evolution, 'evolutio” and the Ainu (an indigenous Japanese people) word for raise, “reska”. RevolKa’s headquarters are located in Tokyo, Japan with laboratories located in Sendai. The company’s investors include Tohoku University Venture Partners Co., Ltd.

“RevolKa”这个名字来源于拉丁语中的进化词“evolutio”和阿伊努语（日本原住民）中的养育词“reska”。RevolKa的总部位于日本东京，实验室位于仙台。该公司的投资者包括东北大学风险投资伙伴有限公司。

and SBI Investment Co., Ltd., and newly joined D3 LLC and DEEPCORE Inc. For more information, visit https://www.revolka.com/en/..

和SBI投资有限公司，以及新加入的D3 LLC和DEEPCORE Inc.有关更多信息，请访问https://www.revolka.com/en/..